Esthesioneuroblastoma metastatic to the neck and lung: a case report and review of the literature
We report on a rare case characterized by distant metastasis to the neck and lung. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 2, 2015 Category: Cancer & Oncology Source Type: research

Potential impact of the hypomethylating agent 5-azacitidine on chronic lymphocytic leukemia with del(17)(p)/del(p53) and subsequent therapy-related acute myeloid leukemia without these aberrations: a case report
Abstract The patient presented here had a very poor prognosis due to previous chronic lymphocytic leukemia with unfavourable cytogenetics (deleted 17p and p53), therapy-related acute myeloid leukemia (intact 17p/p53), multiple pre-treatments (fludarabine, rituximab-CHOP, rituximab-bendamustine), advanced age (71 years) and several comorbidities—circumstances that usually do not allow high-dose chemotherapy or stem cell transplantation. Due to this unfavourable condition and reportedly poorer outcome of therapy-related acute myeloid leukemia relative to de novo acute myeloid leukemia with chemotherapy, treatm...
Source: Memo - Magazine of European Medical Oncology - May 2, 2015 Category: Cancer & Oncology Source Type: research

Amino acid PET monitoring in gliomas
Abstract Positron emission tomography (PET) with radiolabelled amino acids provides information on the behaviour of gliomas with and without blood–brain barrier (BBB) disruption. This is of importance in several clinical conditions and significantly complements findings which remain unresolved by standard MRI alone. In low-grade gliomas, amino acid PET allows early response assessment during chemotherapy which can be used to individually tailor chemotherapy duration. In high-grade gliomas, it enables the differentiation of treatment-related changes from tumor progression during cytotoxic therapy, and to iden...
Source: Memo - Magazine of European Medical Oncology - April 11, 2015 Category: Cancer & Oncology Source Type: research

A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma
Abstract Malignant pleural mesothelioma (MPM) is a devastating and treatment-resistant disease. Currently, well-established prognostic and predictive biomarkers are rare in clinical practice, whereas there is a whole body of various MPM biomarker studies published in medical literature in the past decades. Besides well-established pathological parameters, including histological subtype, disease stage, or level of lymph node involvement, blood parameters and circulating proteins related to a proinflammatory phenotype are emerging as prognostic biomarkers. Here we provide an overview about the current status of pro...
Source: Memo - Magazine of European Medical Oncology - April 1, 2015 Category: Cancer & Oncology Source Type: research

Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - April 1, 2015 Category: Cancer & Oncology Source Type: research

Is more better in myeloma? Treatment intensity and outcome in newly diagnosed myeloma patients
Abstract During the course of disease multiple myeloma subclones acquire more and more additional genetic changes causing an aggressive proliferative growth with less responsiveness to therapeutic agents. On the other hand new therapeutic options are getting available, leading to the question, if a more intensive treatment in newly diagnosed myeloma patients may result in a better outcome concerning progression-free survival, quality of life and overall survival. In newly diagnosed myeloma patients, physicians have to distinguish between patients eligible for autologous stem cell transplantion (ASCT) and patients ...
Source: Memo - Magazine of European Medical Oncology - March 24, 2015 Category: Cancer & Oncology Source Type: research

Predicting drug sensitivity by 3D cell culture models
Abstract Because of recent failures of novel drugs in phase II and III trials innovative in vitro models are needed that may predict drug efficacy in patients. Although, numerous modifications of traditional cell culture and animal models were undertaken significant improvements in cell culture- based drug development have not been achieved. Three-dimensional (3D) cell culture may represents an modern alternative to bridge the gap between 2D cell cultures and animal models. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - March 24, 2015 Category: Cancer & Oncology Source Type: research

New targets in gastric cancer
Abstract Gastric cancer (GC) is the fifth most common malignancy and the third leading cause of cancer-related death worldwide. Since the effectiveness of current therapeutic options for the treatment of advanced (inoperable locally advanced, recurrent, or metastatic) disease is limited the need for novel effective treatment options is obvious. During last 2 decades, molecular-targeted therapy emerged as a new promising treatment modality and showed pronounced success in many tumor types. But in GC the only targeted agent approved until recently was trastuzumab for human epidermal growth factor receptor (HER) 2-po...
Source: Memo - Magazine of European Medical Oncology - March 13, 2015 Category: Cancer & Oncology Source Type: research

Optimal follow-up of endometrial cancer patients
Abstract Gynecological malignancies account round 10 % of all female cancers, with the uterine cancer being the most predominant one. Surveillance programs of all gynecologic cancers are primarily based on recurrence rates, timing of recurrence, salvage options and chances for cure of patient with recurrence. Since there is no prospective, high evidence data about optimal surveillance program after primary treatment of patients with endometrial cancer recommendations are based on review of retrospective data sets. From all the diagnostic tools available, history taking and clinical examination, including comp...
Source: Memo - Magazine of European Medical Oncology - March 10, 2015 Category: Cancer & Oncology Source Type: research

Tailoring treatment in myeloma: are there clues from biology?
Abstract Cytogenetic data have established relevance for prognostication in myeloma. Also, certain chromosomal aberrations were associated with an increased risk of progression of smoldering myeloma to active disease. The impact of cytogenetic and molecular data on treatment decisions is however limited. Myeloma patients with a t(4;14) have been shown to benefit from bortezomib treatment, while thalidomide treatment has a detrimental effect in cases with del17p13. The discovery of marked intraclonal heterogeneity has influence on therapeutic concepts to treat plasma cell disease, but so far no relevance for guidin...
Source: Memo - Magazine of European Medical Oncology - March 10, 2015 Category: Cancer & Oncology Source Type: research

Lymphoma: anything new?
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - March 10, 2015 Category: Cancer & Oncology Source Type: research

Multiple myeloma: the biology, the clinic, and the future
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - March 10, 2015 Category: Cancer & Oncology Source Type: research

Cytomegalovirus retinitis in a child with lymphoblastic lymphoma
Abstract A child suffering from non-Hodgkin lymphoma on chemotherapy presented with cytomegalovirus (CMV) retinitis. Prompt diagnosis and treatment with ganciclovir resulted in successful healing of CMV retinitis with restoration of visual acuity. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - March 2, 2015 Category: Cancer & Oncology Source Type: research

Optimal follow-up of cervical cancer patients
Abstract Gynecological malignancies account for round 10 % of all female cancers, with the cervical cancer being one of the major women health problems in developing regions of the world. Surveillance programs of cervical cancer are primarily based on recurrence rates, timing of recurrence, salvage options, and chances for curing patients with recurrence. Since there is no prospective, high evidence data about optimal surveillance program after primary treatment of patients with cervical cancer recommendations are based on the review of retrospective data sets. Literature search on this topic showed that ther...
Source: Memo - Magazine of European Medical Oncology - February 26, 2015 Category: Cancer & Oncology Source Type: research

Beyond R-CHOP: treatment of double hit, tripple hit, MYC + NHL?
Abstract Double hit (DH) are defined as MYC and BCL2 or/and BCL6 coexpressing B-cell lymphomas. Morphologically they are found in the diffuse large B-cell lymphoma (DLBCL) or in the group of B-cell lymphoma, unclassifiable, with features between DLBCL and Burkitt lymphoma (BCLU). Approximately 5–10 % of DLBCLs and BCLUs are DH lymphomas according to fluorescence in situ hybridization, the percentage rises to 30 %, if protein overexpression is detected by immunohistochemistry. Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone seems to be insufficient. However, for ...
Source: Memo - Magazine of European Medical Oncology - February 18, 2015 Category: Cancer & Oncology Source Type: research

High-dose chemotherapy and autologous hematopoietic stem cell transplantation in a myeloma patient with terminal renal failure and hepatitis C with high viral load
We report on a patient with multiple myeloma and light-chain induced renal failure, diagnosed with hepatitis C and high viral load in the pre-transplant period. We show that the new hepatitis C virus directed drugs daclatasvir and sofosbuvir can be safely applied concomitantly to high-dose therapy with autologous hematopoietic stem cell transplantation. Liver enzymes remained in the normal range during the transplant and in the post-transplant period. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - February 17, 2015 Category: Cancer & Oncology Source Type: research

New drugs on the horizon. Treatment of myeloma in 2020, a perspective
Abstract This minireview covers novel drugs and treatment concepts being evaluated in early studies for therapy of patients with multiple myeloma (MM). Panobinostat, a histone deacetylase inhibitor, showed limited improvement in progression-free survival, thus raising doubt whether these substances will provide clinical meaningful benefits in MM. Some of the new proteasome inhibitors beyond carfilzomib offer the benefit of oral administration and reduced neurotoxicity. Monoclonal antibodies with antimyeloma or antistroma cell activity raise expectations for improved treatment outcome when combined with conventiona...
Source: Memo - Magazine of European Medical Oncology - January 29, 2015 Category: Cancer & Oncology Source Type: research

New targets in breast cancer
Abstract In the past few years, the therapeutic strategies for breast cancer have broadened substantially beyond endocrine therapy, chemotherapy, and human epidermal growth factor receptor 2-targeted agents to include several new drugs with unique mechanism of actions including antibody–drug conjugates, inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway, cyclin-dependent kinases 4/6, histone deacetylases and the poly ADP ribose polymerase as well as immune checkpoint modulators. Novel clinical trial designs are also being implemented in the clinic to assess the therapeutic ...
Source: Memo - Magazine of European Medical Oncology - January 29, 2015 Category: Cancer & Oncology Source Type: research

Treatment of myeloma patients with renal impairment
Abstract Renal impairment is a common phenomenon in myeloma patients. Pathogenesis is mainly based on the presence of monoclonal paraprotein but may include myeloma-independent mechanisms as well. There are various forms of paraprotein-related renal impairment. The majority of severe cases are due to cast nephropathy where precipitation on the basis of monoclonal free light chains causes complex tubular damage. Cast nephropathy requires quick diagnosis and specific treatment. Renal impairment increases mortality in myeloma patients. A quick and sustained response to treatment is crucial for preventing long-term di...
Source: Memo - Magazine of European Medical Oncology - January 21, 2015 Category: Cancer & Oncology Source Type: research

New targets in metastatic colorectal cancer
Abstract At the moment, targeted therapy in metastatic colorectal cancer (mCRC) is a hot topic which is widely discussed in the scientific community. Approximately 25 % of all CRC patients present with metastases at the time of initial diagnosis, and an additional 50 % of them will develop metastases during the subsequent course of their disease, contributing to the high mortality rates reported. Novel targeted agents like monoclonal antibodies directed against vascular endothelial growth factors or against epidermal growth factor receptor combined with chemotherapy as well as multikinase inhibitors (in ...
Source: Memo - Magazine of European Medical Oncology - January 9, 2015 Category: Cancer & Oncology Source Type: research

Targeting oncogenic drivers in lung cancer: celebrating a decade of progress
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - January 9, 2015 Category: Cancer & Oncology Source Type: research

Angiogenesis
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 2, 2014 Category: Cancer & Oncology Source Type: research

Contribution of the vascular bone marrow niche to leukemia progression
Abstract Leukemia arises from leukemic stem cells, which reside within the bone marrow occupying two different stem cells niches: the endosteal and the vascular niche. The maintenance of leukemic stem cells requires complex regulation mediated by many intrinsic and extrinsic signals provided by their niche cells. The interaction of leukemic and endothelial cells can occur either via direct contact through cell adhesion molecules such as selectins or integrins or signals can be transmitted by chemokines or cytokines of which stromal cell-derived factor 1 represents the most studied. Experimental studies provide ev...
Source: Memo - Magazine of European Medical Oncology - December 1, 2014 Category: Cancer & Oncology Source Type: research

Stem cell transplantation for acute myeloid leukaemia in adults
Abstract Gone are the days when a patient with acute myeloid leukaemia (AML) would die waiting for a suitable donor for allogenic stem cell transplantation. With improved supportive care, we can now confidently provide unrelated donor transplant to most patients. The adult patient who does not have a suitable donor can be considered to have a haploidentical transplant or a cord transplant. In fact, a combination of cord and haploidentical transplant can be thought of in carefully selected patients. With new-age molecular diagnostics incorporating genetic mutational analysis along with the cytogenetic model, minim...
Source: Memo - Magazine of European Medical Oncology - December 1, 2014 Category: Cancer & Oncology Source Type: research

Angiogenesis in myeloproliferative neoplasms, new markers and future directions
Abstract Tumor angiogenesis has been identified to play a critical role in tumor growth and tumor progression, and is regulated by a balance of angiogenic and antiangiogenic cytokines. This has been documented for solid tumors, and there is emerging evidence suggesting that tumor progression of hematological malignancies also depends on the induction of new blood vessel formation. Data on angiogenesis in the bone marrow of BCR-ABL1-negative myeloproliferative neoplasm patients suggest an increase of the microvessel density and vascular endothelial growth factor (VEGF) expression, and there is a relation to the JA...
Source: Memo - Magazine of European Medical Oncology - December 1, 2014 Category: Cancer & Oncology Source Type: research

Angiogenesis inhibition in renal cell cancer
Abstract Several targets have been identified for the therapy of metastatic renal cell carcinoma (RCC). The recognition of hypoxia-inducible factor-α signaling in the pathogenesis of clear-cell RCC has led to widespread study of angiogenesis inhibitors. Understanding this molecular pathogenesis of RCC led to a rapid evolvement of new systemic therapies, with seven targeted therapies approved and several more agents in late-stage clinical development. Due to the results of the currently used targeted therapies, the progression-free survival could be prolonged and the overall survival in sequential therapy ca...
Source: Memo - Magazine of European Medical Oncology - December 1, 2014 Category: Cancer & Oncology Source Type: research

International MDS Working Groups: a model of success to improve diagnosis and treatment in rare diseases: 10-year jubilee of the Austrian MDS platform
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 1, 2014 Category: Cancer & Oncology Source Type: research

Is there a role for angiogenesis inhibition in prostate cancer?
Abstract Prostate cancer is the most common male cancer and one of the most common causes of cancer death among men in European countries. In the last years, a large number of new drugs for treatment of castration-resistant prostate cancer (CRPC) have been approved, others are still in an advanced stage of clinical testing. In this review, we provide an overview on new substances which act via modulation or inhibition of angiogenesis. Results and limitations from clinical studies as well as future needs for improvement of those agents in CRPC are critically discussed. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 28, 2014 Category: Cancer & Oncology Source Type: research

ASCO 2014: news, hopes, hypes?
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 28, 2014 Category: Cancer & Oncology Source Type: research

Clinical update: B-cell receptor kinase inhibitors in chronic lymphocytic leukemia
Abstract B-cell receptor (BCR) inhibitors represent an exciting new treatment modality in chronic lymphocytic leukemia (CLL). Currently, ibrutinib monotherapy as well as idelalisib in combination with rituximab are approved by the European Medical Agency for the treatment of all patients with relapsed/refractory CLL and for first-line treatment of patients with deletion 17p or TP53 mutation unsuitable for chemoimmunotherapy. The results of ongoing trials with these and other BCR inhibitors are expected to lay the basis for approval in further indications, but have to be awaited. Above all, BCR inhibitors have show...
Source: Memo - Magazine of European Medical Oncology - November 28, 2014 Category: Cancer & Oncology Source Type: research

Optimal follow-up of ovarian cancer patients
Abstract Gynecological malignancies account for roughly 10 % of all cancers in women with ovarian cancer as leading cause of death due to gynecological tumors. Surveillance programs of ovarian cancer are primarily based on recurrence rates, timing of recurrence, salvage options, and chances for cure of patient with recurrence. Since there is no prospective, high evidence data on optimal surveillance program after primary treatment of patients with ovarian cancer recommendations are based on review of retrospective data sets. From all the diagnostic tools available, history taking and clinical examination, i...
Source: Memo - Magazine of European Medical Oncology - November 28, 2014 Category: Cancer & Oncology Source Type: research

Latest developments in the treatment of metastatic colorectal cancer: update ASCO 2014
Abstract Studies presented on metastatic colorectal cancer at this year’s ASCO focused on RAS as a predictive biomarker for anti-epidermal growth factor receptor (EGFR)-directed therapies. Extended RAS analysis for the CRYSTAL study were presented for the first time and showed improved benefit in terms of overall survival, progression-free survival and response rate within the all RAS wild-type cohort. Together we already known results from other anti-EGFR-directed studies it can be stated that expanded RAS status assessment is a prerequisite for the use of an anti-EGFR antibody. The German AIO group showed ...
Source: Memo - Magazine of European Medical Oncology - November 26, 2014 Category: Cancer & Oncology Source Type: research

Post ASCO update 2014: head and neck cancer
In this study the experimental compound was shown to improve response rate and progression free survival with an acceptable toxicity profile. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 26, 2014 Category: Cancer & Oncology Source Type: research

To maintain or not to maintain: treatment forever in myeloma?
Abstract Achieving a first complete remission in myeloma has become feasible with novel agent-based combination therapies followed by autologous stem cell transplantation (ASCT), leading to CR rates of 40%. But continuously occurring relapses in these patients have lead to the revival of maintenance (MT) concepts aiming to eliminate or control minimal residual disease when myeloma burden is low and not too many clonal tidings have been induced. On the other side, the clinical effectiveness of MT has to be balanced against its considerable cost, toxicity and effects on quality of life. Owing to low effectiveness an...
Source: Memo - Magazine of European Medical Oncology - November 26, 2014 Category: Cancer & Oncology Source Type: research

Angiogenesis inhibition, hypoxia, and targeting the bone marrow microenvironment in multiple myeloma: new strategies and targets
Abstract Multiple myeloma (MM) is a hematological B-cell malignancy that has still a fatal prognosis. Although the treatments have improved, one major problem in MM is the clinical resistance to available drugs and combination therapies over time. Novel agents, such as oral proteasome inhibitors, monoclonal antibodies, second generation immunomodulatory drugs and therapies targeting the cell signaling and the tumor microenvironment are in development for the treatment of relapsed/refractory MM. In this review, we refer on the role of new strategies targeting the tumor microenvironment, especially on angiogenesis, ...
Source: Memo - Magazine of European Medical Oncology - November 13, 2014 Category: Cancer & Oncology Source Type: research

Radiotherapy for brain metastases: are we getting better?
Abstract Brain metastases are the most common malignant adult CNS tumor. The blood brain barrier (BBB) prevents many drugs from achieving therapeutic concentrations in the central nervous system (CNS), leaving the brain as a potential sanctuary site of disease and underscoring the importance of radiotherapy. Neurons, glial cells and vascular endothelium are prone to radiation-induced damage. Efforts have been made to reduce radiation-induced toxicity and increase efficacy (Stereotactic radio-surgery - SRS, advanced radiation-techniques that allow decreasing the dose to the hippocampi, while intensifying the radiat...
Source: Memo - Magazine of European Medical Oncology - November 13, 2014 Category: Cancer & Oncology Source Type: research

Melanoma 2014—an update
Abstract The incidence of cutaneous melanoma has been increasing worldwide. Although only 5% of all skin cancers are cutaneous melanoma, more than 90% of all skin cancer-related deaths are attributed to this tumour. The prognosis of metastatic melanoma remains poor with conventional chemotherapy, with survival rates between 6 to 9 months. Even combination regimes (polychemotherapy, poly-chemo-immunotherapy) failed to show a significant survival benefit. In the past 10 years, major efforts and advances have been made in the understanding of the biology of melanoma. These findings led to the development...
Source: Memo - Magazine of European Medical Oncology - November 4, 2014 Category: Cancer & Oncology Source Type: research

Is dosing in oncology gender-sensitive?
Abstract Cancer is still the second cause of death in Europe and with the aging of populations, the number of cancer patients will further increase. For Austria, the gender-specific analysis of epidemiology and survival rates of cancer in the past 10 years show that there are significant differences between men and women that could at least partly been used for the implementation of future preventive and/or therapeutic actions. Gender-specific pharmacokinetic differences for medications with narrow therapeutic index as most of the drugs used in cancer therapy have been documented for more than a decade. It would b...
Source: Memo - Magazine of European Medical Oncology - October 30, 2014 Category: Cancer & Oncology Source Type: research

Lung cancer: ASCO 2014 update
Abstract At the American Society of Clinical Oncology (ASCO) meeting 2014, the most striking abstracts on lung cancer treatment addressed—as expected—aspects of targeted therapy. The most probable practice changing data came from the presentation of the PROFILE 1014 trial dealing with anaplastic lymphoma kinase-positive non-small-cell lung carcinoma patients treated with crizotinib or chemotherapy in the first-line setting, which confirmed a comparable degree of benefit from crizotinib treatment as reported in second-line treatment. After 10 years of epidermal growth factor receptor (EGFR)-directed the...
Source: Memo - Magazine of European Medical Oncology - October 30, 2014 Category: Cancer & Oncology Source Type: research

ASCO 2014: highlights in breast cancer
Abstract While in general, not immediately praxis changing, results of various relevant clinical trials were presented at the 2014 ASCO Annual Meeting. Indeed, the ALTTO study provided first (albeit negative) data on the activity of dual Her2 inhibition with trastuzumab and lapatinib (either sequentially or concomitantly) in the adjuvant setting, while a combined analysis of the SOFT and TEXT studies suggested, for the first time, that a combination of ovarian function suppression (OFS) plus exemestane might be superior to OFS plus tamoxifen in premenopausal early breast cancer patients. Results of the POEMS trial...
Source: Memo - Magazine of European Medical Oncology - October 28, 2014 Category: Cancer & Oncology Source Type: research

Gene signature profiling of gynaecological malignancies
Abstract Genetic profiling of cancer may lead to a better understanding of its intra- as well as intertumoural heterogeneity as well as targeted, patient-oriented cancer therapy. Due to the recent advances in molecular biology, important steps towards this goal have been accomplished. Among others, several large profiling analyses of gynaecologic malignancies have been completed and published recently. Most notably, these comprehensive molecular analyses expose a high degree of cancer complexity and heterogeneity. Integration of this data into clinical practice will result in new tumour classifications and possibl...
Source: Memo - Magazine of European Medical Oncology - October 9, 2014 Category: Cancer & Oncology Source Type: research

PET in lymphoma: who, when, how often, pitfalls?
Abstract For optimal therapy management in patients with lymphoma, sensitive and specific imaging modalities for accurate initial staging and evaluation of response to therapy are crucial. Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) that combines metabolic information of 18F-FDG PET with morphological information of diagnostic CT has proven to be a very useful tool in the work-up of lymphomas. Especially in 18F-FDG-avid tumours like Hodgkin lymphoma and high-grade, aggressive non-Hodgkin lymphoma, 18F-FDG PET/CT is widely used for pre-treatment staging and respo...
Source: Memo - Magazine of European Medical Oncology - October 8, 2014 Category: Cancer & Oncology Source Type: research

Towards automation of flow cytometric analysis for quality-assured follow-up assessment to guide curative therapy for acute lymphoblastic leukaemia in children
This article introduces a new European Union-funded project (AutoFLOW) aiming at the standardization and automation of FCM-MRD analysis by machine-learning technology. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 11, 2014 Category: Cancer & Oncology Source Type: research

Neoadjuvant chemotherapy for soft tissue sarcoma
Abstract Soft tissue sarcoma is a rare and very heterogeneous disease. The prognosis of these cancers is mainly influenced by histological grading size location and type of histology. Many aspects argue in favor of neoadjuvant chemotherapy but no singular trial could unambiguously prove an advantage of neoadjuvant therapy. This short review has a focus on neoadjuvant chemotherapy as induction therapy prior to chemoradiation or neoadjuvant chemotherapy alone. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2014 Category: Cancer & Oncology Source Type: research

The role of maintenance strategies in breast cancer
Abstract Maintenance treatment is generally administered to patients without progression after an initial chemotherapy regimen of standard duration, with the aim of increasing the time to progression of disease. The aims of this strategy include prolongation of survival with good quality of life and symptom control. The duration of the treatment is generally based on patient responsiveness and individual tolerability as well as physician preferences. As breast cancer is a heterogeneous disease with different biological characteristics, the strategy of maintenance therapy may be adapted accordingly. Metronomic che...
Source: Memo - Magazine of European Medical Oncology - September 1, 2014 Category: Cancer & Oncology Source Type: research

Venous thromboembolism in children with acute lymphoblastic leukemia
Abstract Venous thromboembolism (VTE) occurs in 0.95–36 % of children with acute lymphoblastic leukemia almost exclusively during chemotherapy. It is most commonly associated with concurrent l-asparaginase and steroid therapy, central venous line use, and inherited thrombophilia. Clinical manifestations regarding the location of VTE include central nervous system thrombosis (sinus venous thrombosis, cerebral infarct/stroke), upper-/lower-limb deep venous thrombosis, pulmonary embolism, and right atrial/intracardiac and superficial venous thrombosis and can be both symptomatic and asymptomatic. The majo...
Source: Memo - Magazine of European Medical Oncology - September 1, 2014 Category: Cancer & Oncology Source Type: research

Long-term tolerability of the BRAF inhibitor vemurafenib in patients with metastatic melanoma: current study data and real-life observations
Abstract Vemurafenib is a targeted therapy against metastatic melanoma. It specifically inhibits the V600 mutated BRAF kinase in the mitogen-activated protein kinase pathway. Only limited data are available on long-term tolerability and efficacy of this drug. Here, we report and discuss six patients from our own clinical practice who were treated with vemurafenib for 16–27 months. Overall, these long-term responders tolerated vemurafenib well during the prolonged period of therapy. Most of the side-effects occurred during the first 6 months of treatment and were transient. The most common persistent side-ef...
Source: Memo - Magazine of European Medical Oncology - September 1, 2014 Category: Cancer & Oncology Source Type: research

ASH 2013: short review on myeloproliferative neoplasms
Abstract At the 2013 annual meeting of the American Society of Hematology, the role of calreticulin in essential thrombocythemia and primary myelofibrosis as well as safety aspects in second-generation tyrosin kinase inhibitor treatment of chronic myeloid leukemia have been major issues in the field of myeloproliferative neoplasms. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2014 Category: Cancer & Oncology Source Type: research

Clinicopathological profile of bilateral breast cancer at a tertiary cancer center in South India
Conclusions BBC is an uncommon clinical entity. For women with younger premenopausal age, the incidence of BBC is higher compared with older women. As the prognosis of BBC is poor, it is crucial to be aware of this entity, and every patient with breast cancer should be regularly followed up. These patients require individualized treatment planning based on the tumor factors and treatment factors of the primary lesion. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2014 Category: Cancer & Oncology Source Type: research

Myelodysplastic syndromes (MDS)
Abstract Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases characterized by ineffective haematopoiesis and cytopenias in peripheral blood. Transformation into acute myeloid leukaemia is a common complication of MDS. Life expectancy varies between nearly normal and early death. MDS were an important issue at last year’s annual meeting of the American Society of Hematology. Like in the years before, the majority of contributions dealt with preclinical aspects. In addition to that, several interesting clinical studies regarding diagnosis and treatment were presented. (Source: Memo - Magazin...
Source: Memo - Magazine of European Medical Oncology - September 1, 2014 Category: Cancer & Oncology Source Type: research